Evidence map›Paper›PMID 40991008›Full record

ArticleAnnals of medicine2025

A retrospective analysis of survival prognostic factors and risk stratification in recurrent glioblastoma.

Lei She, Han Wu, Xin Zhang, Chunmao Zheng, Lin Su

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lei SheDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Han WuDepartment of Cardiothoracic Surgery, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China.
Xin ZhangDepartment of Pharmacy, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China.
Chunmao ZhengDepartment of Pharmacy, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China.
Lin SuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0002-6458-4610

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTraditional Cox analysis identifies independent prognostic factors in recurrent glioblastoma (rGBM) but often overlooks their interrelationships. We aimed to develop a predictive nomogram integrating these multifaceted factors to establish a clinically applicable risk stratification model. MATERIALS AND

methodsIn a retrospective analysis of IDH-wildtype rGBM, we used Cox regression to evaluate prognostic factors including age, sex, Ki-67 index, Karnofsky Performance Status (KPS), time to first progression, number of recurrent lesions, tumor location, O

resultsOur cohort included 206 patients with a median overall survival (OS) of 8.3 (95% CI, 7.2-9.4) months. Multivariate analysis revealed KPS > 50 (

conclusionsWe developed and internally validated a nomogram-based risk stratification model for rGBM. By integrating key clinical and molecular factors, this tool accurately predicts patient survival.

Indexed as

Brain NeoplasmsGlioblastomaNeoplasm Recurrence, LocalAdultAgedDNA MethylationDNA Modification MethylasesDNA Repair EnzymesFemaleHumansKarnofsky Performance StatusMaleMiddle AgedNomogramsPrognosisProportional Hazards ModelsDNA Modification MethylasesDNA Repair EnzymesMGMT protein, humanTumor Suppressor ProteinsNomogrampredictionrecurrent glioblastomarisk stratificationsurvival

Identifiers

PMID40991008
PMCPMC12462419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.